ID
15543
Beschreibung
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Please document clinically significant findings as Adverse Events. Clinical Significance is defined as any variation in physical findings that has medical relevance and may result in an alteration in medical care. Safety Blood and Urine Examinations: Please document the results for Serum Creatinine, Platelets and TSH on CRF-Pages "Safety Laboratory Assessments". Part: Relapse Evaluation Visit No. 2
Link
https://clinicaltrials.gov/ct2/show/NCT02419378
Stichworte
Versionen (1)
- 02.06.16 02.06.16 -
Hochgeladen am
2. Juni 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Relapse Evaluation Visit No. 2 Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Relapse Evaluation Visit No. 2 Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Ähnliche Modelle
Relapse Evaluation Visit No. 2 Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
C0449438 (UMLS CUI [1,2])
C0449438 (UMLS CUI [1,2])
C0018793 (UMLS CUI [1,2])
C0018793 (UMLS CUI [1,2])
C0024109 (UMLS CUI [1,2])
C0024109 (UMLS CUI [1,2])
C0000726 (UMLS CUI [1,2])
C0000726 (UMLS CUI [1,2])
C0278454 (UMLS CUI [1,2])
C0022417 (UMLS CUI [1,3])
C0022417 (UMLS CUI [1,2])
C0278060 (UMLS CUI [1,2])
C0278060 (UMLS CUI [1,2])
C0031809 (UMLS CUI [1,2])
C1705848 (UMLS CUI [1,3])